Research matters

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.

Article
MORE →
Abstract
MORE →
Abstract
MORE →
Abstract
MORE →
Abstract
MORE →
Prapti A. Patel, Yazan F. Madanat, Andrew J. Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang
We investigated the outcomes of patients treated with venetoclax based combination therapies in a large cohort of patients in the real-world setting. Survival differences were observed in the different treatment arms with Ven/LDAC having the shortest OS and ven/dac and ven/HMA having comparable survival rates.
Donna R. Rivera, Henry J. Henk, Elizabeth Garrett-Mayer, Jennifer B. Christian, Andrew J. Belli, Suanna S. Bruinooge, Janet L. Espirito, Connor Sweetnam, Monika A. Izano, Yanina Natanzon, Nicholas J. Robert, Mark S. Walker, Aaron B. Cohen, Marley Boyd, Lindsey Enewold, Eric Hansen, Rebecca Honnold, Lawrence Kushi, Pallavi S. Mishra Kalyani, Ruth Pe Benito, Lori C. Sakoda, Elad Sharon, Olga Tymejczyk, Emily Valice, Joseph Wagner, Laura Lasiter, Jeff D. Allen
COTA participated in the FOCR pilot project to evaluate the performance of real-world overall survival (rwOS) from EHRs to a previous randomized controlled trial in NSCLC. These two research papers outline the details of this collaboration in validating endpoints in the real-world setting.

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.